Drug intelligence / Profile preview

Sanfeng Tongqiao

Development stage: Unknown
Lead developer: Yangtze River Pharmaceutical Group
Administration: Oral

Overview

Sanfeng Tongqiao is a Traditional Chinese Medicine (TCM) formulation developed by Yangtze River Pharmaceutical Group, primarily in the form of dripping pills. It is indicated for the treatment of seasonal allergic rhinitis, specifically targeting the wind-cold exterior syndrome and heat transforming in stagnant lung syndrome according to TCM principles. The formulation aims to disperse wind and open the nasal orifices to alleviate symptoms such as nasal congestion, sneezing, and rhinorrhea. It is currently undergoing Phase II clinical evaluation in China to assess its efficacy and safety.

Brand names: Sanfeng Tongqiao Dripping Pills
Other names: Sanfeng Tongqiao散风通窍滴丸

Beyond the preview

Go deeper on Sanfeng Tongqiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanfeng Tongqiao.

Explore the full profile